<DOC>
	<DOCNO>NCT00238498</DOCNO>
	<brief_summary>This study conduct United States . The purpose study assess safety effectiveness number dose vildagliptin , unapproved drug , treatment people type 2 diabetes .</brief_summary>
	<brief_title>A Clinical Study Assess Efficacy Safety Vildagliptin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Diagnosis type 2 diabetes Patients place diet exercise therapy without achievement glycemic control Outpatients Type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes Significant cardiovascular disease Significant diabetic complication Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>HbA1c</keyword>
</DOC>